3 Healthcare Stocks Stories To Close Out the Trading Week

Impax Laboratories (NASDAQ:IPXL): Closing price $18.42

On Friday, Impax said that its generics division, Global Pharmaceuticals, began shipment of authorized generic Zomig (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the United States, as part of a distribution, license, development and supply agreement with AstraZeneca UK Limited, a part of AstraZeneca (NYSE:AZN). Zomig is indicated for treating migraine headaches in adults. IMS Health (RX) data reports that domestic sales of Zomig tablets and orally disintegrating tablets came to roughly $196 million in the 12 months ended in April.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

IPXL

Thoratec Corporation (NASDAQ:THOR): Closing price $32.60

The corporation has announced that it has won FDA approval to market the HeartMate II Pocket Controller, which is the “small, smart, safe face” of the HeartMate II LVAD System. Thoratec creates device-based mechanical circulatory support therapies to save, support and restore failing hearts.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

THOR

Oramed Pharmaceuticals (NASDAQ:ORMP): Closing price $8.60

The oral drug delivery systems developer announced Friday that the FDA has approved its investigational new drug application for ORMD-0801, which is its oral insulin capsule. Oramed’s ORMD-0801 is an orally ingestible insulin capsule, indicated for the early stages of type 2 diabetes, when it is still possible to deter the rate of degeneration of the disease by supplying additional insulin to the body and permitting pancreatic respite.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ORMP

Don’t Miss: Is Johnson & Johnson Still a Good Defensive Play?

More from The Cheat Sheet